RIPK1 and metabolic dysfunction-associated steatohepatitis: Since liver inflammation and hepatocellular death are underlying mechanisms in promoting NASH, we suggest the possibility of inhibiting RIPK1 kinase as a therapeutic strategy for reducing NASH pathogenesis by inhibiting liver inflammation and hepatocellular death.